Novo Nordisk A/S (NYSE:NVO) Upgraded at StockNews.com

Novo Nordisk A/S (NYSE:NVO) was upgraded by stock analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a research note issued on Monday.

A number of other research firms also recently issued reports on NVO. Morgan Stanley initiated coverage on Novo Nordisk A/S in a research report on Wednesday, February 12th. They issued an “equal weight” rating on the stock. Stifel Nicolaus downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, March 3rd. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. BMO Capital Markets reduced their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research report on Monday, December 23rd. Finally, UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Novo Nordisk A/S has an average rating of “Moderate Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Price Performance

NVO stock opened at $61.41 on Monday. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The stock has a market cap of $275.60 billion, a PE ratio of 18.67, a price-to-earnings-growth ratio of 0.90 and a beta of 0.61. The stock has a 50-day moving average price of $79.45 and a two-hundred day moving average price of $95.04. Novo Nordisk A/S has a 1 year low of $60.61 and a 1 year high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Equities analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in NVO. GQG Partners LLC lifted its position in Novo Nordisk A/S by 74.7% in the 4th quarter. GQG Partners LLC now owns 12,994,533 shares of the company’s stock valued at $1,117,790,000 after acquiring an additional 5,556,460 shares in the last quarter. Raymond James Financial Inc. bought a new stake in shares of Novo Nordisk A/S in the 4th quarter worth $404,910,000. Loomis Sayles & Co. L P raised its holdings in shares of Novo Nordisk A/S by 34.2% in the fourth quarter. Loomis Sayles & Co. L P now owns 11,571,686 shares of the company’s stock valued at $995,397,000 after purchasing an additional 2,947,771 shares during the last quarter. Nuveen Asset Management LLC lifted its position in shares of Novo Nordisk A/S by 73.2% during the fourth quarter. Nuveen Asset Management LLC now owns 6,244,931 shares of the company’s stock valued at $537,189,000 after purchasing an additional 2,639,693 shares in the last quarter. Finally, Two Sigma Investments LP purchased a new position in Novo Nordisk A/S during the fourth quarter worth about $158,657,000. 11.54% of the stock is owned by institutional investors and hedge funds.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.